| Literature DB >> 35715523 |
Can Yurttas1, Christian Thiel1, Dörte Wichmann1, Philipp Horvath1, Jens Strohäker1, Malte Niklas Bongers2, Martin Schenk1, Dietmar Stüker1, Alfred Königsrainer1, Karolin Thiel3.
Abstract
Surgical therapy of duodenal perforation into the retroperitoneum entails high morbidity. Conservative treatment and endoscopic negative pressure therapy have been suggested as promising therapeutic alternatives. We aimed to retrospectively assess outcomes of patients treated for duodenal perforation to the retroperitoneum at our department. A retrospective analysis of all patients that were treated for duodenal perforation to the retroperitoneum at our institution between 2010 and 2021 was conducted. Different therapeutic approaches with associated complications within 30 days, length of in-hospital stay, number of readmissions and necessity of parenteral nutrition were assessed. We included thirteen patients in our final analysis. Six patients underwent surgery, five patients were treated conservatively and two patients received interventional treatment by endoscopic negative pressure therapy. Length of stay was shorter in patients treated conservatively. One patient following conservative and surgical treatment each was readmitted to hospital within 30 days after initial therapy whereas no readmissions after interventional treatment occurred. There was no failure of therapy in patients treated without surgery whereas four (66.7%) of six patients required revision surgery following primary surgical therapy. Conservative and interventional treatment were associated with fewer complications than surgical therapy which involves high morbidity. Conservative and interventional treatment using endoscopic negative pressure therapy in selected patients might constitute appropriate therapeutic alternatives for duodenal perforations to the retroperitoneum.Entities:
Mesh:
Year: 2022 PMID: 35715523 PMCID: PMC9205956 DOI: 10.1038/s41598-022-14278-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Screening, therapy decision, follow-up and analysis of patients. n number.
Patient characteristics with relevant comorbidities and medication. ASA: acetylsalicylic acid; BMI: body mass index.
| Sex | Age | Comorbidities | Medication | |
|---|---|---|---|---|
| #1 | F | 65 | Enterothorax, arterial hypertension, phyllodes tumor of the breast, mastitis non-puerperalis | Candesartan |
| #2 | F | 66 | Urinary tract infection, eosinophilic gastritis, hypothyroidism | Prednisolone, pantoprazole, L-thyroxine |
| #3 | M | 50 | Mantle cell lymphoma | Aciclovir, cotrimoxazole, pantoprazole |
| #4 | F | 59 | Type 2 diabetes mellitus, peripheral artery disease | Sitagliptin and metformin hydrochloride, lisinopril, ASA |
| #5 | M | 29 | None | None |
| #6 | F | 75 | Arterial hypertension | Bisoprolol, ramipril |
| #7 | F | 82 | Atrial fibrillation, breast cancer | Apixaban |
| #8 | F | 69 | Hypothyroidism, soft tissue rheumatic disorder | Dexamethasone |
| #9 | F | 75 | Portal vein thrombosis, helicobacter pylori-gastritis, arterial hypertension, hypercholesterolemia | ASA, hydrochlorothiazide, candesartan, amlodipine, metoprolol, ezetimibe |
| #10 | F | 71 | Hypercholesterolemia, coronary artery disease | ASA, nebivolol, venlaxfaxine, gabapentin |
| #11 | F | 62 | Cachexia (BMI 13.6 kg/m2), hypercholesterinemia | ASA, simvastatin |
| #12 | M | 88 | Prostate cancer, gastric ulcer, type 2 diabetes mellitus, renal insufficiency | sitagliptin, triamterene, metoprolol |
| #13 | F | 55 | Chronic pain syndrome | None |
Findings of physical examination, laboratory assessment, computed tomography and endoscopy at initial presentation. n/a: not available; bpm: beats per minute, CRP: C-reactive protein, CT computed tomography.
| History | °C | Blood pressure mmHg | bpm | Leukocytes /µl | CRP mg/dl | CT | Endoscopy | |
|---|---|---|---|---|---|---|---|---|
| #1 | Abdominal pain < 24 h | 37.0 | 125/85 | 90 | 14,000 | 32.1 | Gastric and colonic herniation to the thorax, covered perforation of the duodenum with retroperitoneal abscess, concomitant cholecystitis | Perforated diverticulum of pars descendens duodeni |
| #2 | Epigastric pain for 10 days | 36.6 | 130/80 | 84 | 11,580 | 14.7 | Retroperitoneal perforation of duodenal ulcer | Not performed |
| #3 | Aphagia, singultus, gastroesophageal reflux | 36.6 | 115/60 | 88 | 4,820 | 5.2 | Covered perforation of duodenal ulcer | Ulcus duodeni |
| #4 | Abdominal and back pain < 24 h | 37.3 | 130/85 | 76 | 18,950 | 44.4 | Covered perforation of duodenal diverticulum | Not performed |
| #5 | Epigastric pain for 5 weeks | 36.0 | 100/60 | 96 | 15,060 | 23.2 | Covered perforated duodenal ulcer | Not performed |
| #6 | Pain, vomiting < 24 h | 36.5 | 190/70 | 84 | 10,420 | 1.2 | Perforated duodenal diverticulum with retroperitoneal abscess | Not performed |
| #7 | Epigastric pain, nausea < 24 h | 36.6 | 182/97 | 82 | 6,300 | 0.3 | Covered perforation of duodenal diverticulum | Perforated diverticulum of the duodenum |
| #8 | Abdominal pain and vomiting for 3 days | 36.2 | 123/83 | 77 | 14,200 | 33.9 | Perforation of duodenal diverticulum | Perforated juxtapapillary diverticulum of the duodenum |
| #9 | Belt-like abdominal pain for 4 days | 37.2 | 140/80 | 96 | 14,110 | 44.6 | Covered perforation of duodenal pseudodiverticulum with concomitant partial thrombosis of the portal vein | Bile duct fistula to the duodenum suspected |
| #10 | Abdominal pain < 24 h | n/a | n/a | 82 | 6,000 | 42.0 | Covered perforation of the duodenum | Not performed |
| #11 | Abdominal pain for 4 weeks | 37.0 | 150/70 | 92 | 16,420 | 0.3 | Covered perforation of duodenal ulcer | Ulcus duodeni |
| #12 | Abdominal pain < 24 h | 38.7 | 145/85 | 60 | 9,900 | 2.2 | Perforation of duodenal diverticulum | Not performed |
| #13 | Epigastric pain < 24 h | 37.3 | 113/81 | 74 | 15,270 | 5.1 | Perforated duodenal ulcer with retroperitoneal abscess | Ulcus duodeni |
Figure 2Time course of regression of a retroperitoneal abscess due to perforation of a duodenal diverticulum in patient #8 at initial diagnosis with retroperitoneal gas collections (A), with incipient size decrease and regressing gas collections after four days (B), further size reduction and decreasing perifocal inflammation after nine days (C), and increasingly consolidated state after 15 days (D) with endoscopic negative pressure therapy.
Description of therapy and treatment failure, antibiotic therapy, microbiological findings, length of stay, adverse epvents according to Clavien-Dindo classification and readmissions.
| First therapy | Second therapy | Antibiotic therapy | Microbiology | Parenteral nutrition | Length of stay | Adverse events (frequency) | Readmission within 30 days | |
|---|---|---|---|---|---|---|---|---|
| #1 | Abscess evacuation, sewing of duodenal perforation, cholecystectomy, repositioning of herniated stomach and colon, hiatoplasty; endoscopic negative pressure therapy | Resection of insufficient duodenal segment, drainage by attachment of duodenojejunostomy | Meropenem vancomycin fluconazole | Veillonella parvula and dispar Escherichia coli, Streptococcus anginosus, Proteus mirabilis | Yes | 22 days | IIIb (1) | No |
| #2 | Billroth II gastrectomy | Intestinal feeding with negative pressure therapy at duodenal stump; Open abdominal lavage endoscopic negative wound pressure therapy | ciprofloxacin, metronidazolemeropenem vancomycin fluconazole | Escherichia coli, Enterococcus faecium and faecalis, Klebsiella pneumoniae, Streptococcus mitis and anginosus, Prevotella buccae, Staphylococcus haemolyticus, Leuconostoc species, Lactobacillus rhamnosus and paracasei | Yes | 22 days | II (1) IIIa (1) IVa (1) | No |
| #3 | Billroth II gastrectomy | No | ampicillin/sulbactam fluconazole meropenem vancomycin anidulafungin cotrimoxazole | Candida glabrata Enterococcus faecium and Citrobacter freundii | Yes | 12 days | IVa (1) | No |
| #4 | Diverticulum resection, cholecystectomy, insertion of Kehr’s tube into the biliary duct and sewing of the duodenum | Pancreatectomy, splenectomy and cholecystectomy | meropenem, vancomycin, fluconazole linezolid fluconazole | Candida albicans Enterococcus faecium | No | 19 days | IVa (1) | No |
| #5 | Open abscess evacuation and drainage | Endoscopic transgastric drainage | piperacillin/tazobactam | Streptococcus constellatus Mycobacterium tuberculosis complex | No | 10 days | IIIb (1) | Yes |
| #6 | diverticulum resection, cholecystectomy, insertion of Kehr’s tube into the biliary duct and sewing of the duodenum | No | piperacillin/tazobactam | Proteus mirabilis, Klebsiella pneumonia, Lactobacillus species, Bacteroides ovatus | No | 15 days | No | No |
| #7 | Endoscopic negative pressure therapy | No | piperacillin/tazobactam fluconazole | Enterococcus faecium | Yes | 20 days | I (1) | No |
| #8 | Endoscopic negative pressure therapy | No | Cefotaxime metronidazole fluconazole | None | Yes | 20 days | No | No |
| #9 | Conservative | No | piperacillin/tazobactam fluconazole | Helicobacter pylori | No | 12 days | No | No |
| #10 | Conservative | No | meropenem vancomycin fluconazole | None | No | 12 days | No | No |
| #11 | Conservative | No | piperacillin/tazobactam fluconazole amoxicillin, clarithromycin | Helicobacter pylori | No | 11 days | No | No |
| #12 | Conservative | No | ciprofloxacin metronidazole | None | No | 10 days | No | No |
| #13 | Conservative | ERCP | ciprofloxacin metronidazole piperacillin/tazobactam | None | No | 9 days 14 days | IIIb (1) | Yes |
Figure 3(a) Length of stay in days according to type of therapy. (b) Distribution and number of adverse events according to Clavien-Dindo classification of postoperative complications.